Navigation Links
MIT's McGovern Institute honors Emory neuroscientist for contributions to psychiatry
Date:2/8/2008

The McGovern Institute for Brain Research at MIT announced today that Michael Davis, a neuroscientist at Emory University in Atlanta GA, will be the 2008 recipient of the Edward M. Scolnick Prize in Neuroscience. The Scolnick Prize is awarded annually by the McGovern Institute to recognize an individual who has made outstanding advances in the field of neuroscience. Dr. Davis, who is the Robert W. Woodruff Professor of Psychiatry and Behavioral Sciences at Emory University School of Medicine, will receive the 2008 prize for his work on the neural basis of fear and its applications to psychiatric research.

We are delighted to honor Mike Davis with this award, said Robert Desimone, director of the McGovern Institute and chair of the selection committee. Not only has he made many important contributions to basic neuroscience, his work also represents one of the best examples of bench-to-bedside translational research in psychiatry.

In work that spans three decades, Davis has provided fundamental insights into the neural basis of fear and anxiety. His early research exploited the startle reflex of rats in response to a sudden noise. He showed that this response is sensitive to drugs that reduce anxiety in humans, and in a classic 1982 paper he traced the entire brain pathway that underlies the startle reflex, paving the way for detailed studies of the neural mechanisms that underlie anxiety.

Like Pavlovs dogs that were conditioned to associate a bell with food, rats and humans can learn fearful associations. The fear conditioning paradigm has been immensely influential in neuroscience, providing for example one of the earliest and best demonstrations of the importance of synaptic changes in learning. Davis has contributed importantly to this field, showing that fear learning is controlled by a class of molecules known as NMDA receptors, acting within a brain structure called the amydgala.

The flip side of associative learning is extinction, a process by which learned associations such as fearful memories eventually disappear. Extinction is not merely the gradual decay of memory. Instead, Davis has shown that extinction involves an active process that, like the acquisition of fear memories, depends on NMDA receptors. Understanding the balance between acquisition and extinction of fearful memories is of great importance for psychiatric conditions such as anxiety disorders and PTSD, and based on his studies with rats, Davis proposed that drugs that promote NMDA receptor signaling could be used therapeutically to enhance fear extinction in humans.

In collaboration with clinical colleagues at Emory, Davis recently confirmed this idea, showing that the drug D-cycloserine can enhance the effects of psychotherapy as a treatment for fear of heights. This approach also shows promise for treating other disorders, including obsessive-compulsive disorder, social phobia, panic disorder and post-traumatic stress disorder (PTSD); Davis is currently testing D-cycloserine, in combination with virtual reality-based psychotherapy, on Iraq veterans suffering from PTSD.

The McGovern Institute will award the Scolnick Prize to Dr. Davis on Monday April 14, 2008, at 4pm. Dr. Davis will deliver a lecture entitled "Neurobiology of Fear, Anxiety and Extinction: Implications for Psychotherapy", followed by a reception, at the McGovern Institute in the Brain and Cognitive Sciences Complex, 43 Vassar Street (building 46, room 3002) in Cambridge. The event is free and open to the public.


'/>"/>

Contact: Gayle Lutchen
gwolf@mit.edu
McGovern Institute for Brain Research
Source:Eurekalert

Related medicine news :

1. Sutter Admits: Closing St. Lukes Likely to Reduce Charity Care
2. Michael J. Fox Foundation Commits up to $3.8 Million to Develop Gene Silencing Neuroprotective Treatment for Parkinsons Disease
3. Takeda submits new drug application for alogliptin (syr-322) in the US
4. XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
5. ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating
6. Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
7. ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
8. Health Care Bill Omits Access to Spiritual Care
9. Activating protein enhances average lifespan, limits age-related disease in mice
10. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
11. Gates Foundation Commits to Expansion of HIV Prevention in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... While it’s ... poses a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , ... medication in darkness or restricted lighting. As such, it eliminates the need to turn ...
(Date:10/13/2017)... , ... October 13, 2017 , ... PurhealthRX , ... Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize ... providing a CBD form that can be easily incorporated into liquid products, while reducing ...
(Date:10/13/2017)... Shelton, CT (PRWEB) , ... October 13, 2017 , ... ... and long-term care services, staged a mock evacuation of the facility as part of ... Department, Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well ...
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... be giving viewers the lowdown on sciatica in a new episode of "Success ... focuses on current events and innovation and investigates each subject in-depth with passion ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
(Date:9/12/2017)... PARIS and NEW YORK , Sept. 12, ... ethical performance ratings for global supply chains, has published the first annual ... the CSR performance of more than 20,400 companies evaluated by EcoVadis, based ... years 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
Breaking Medicine Technology: